InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,408.42
(
-1.73%
)
US TECH 100
17,870.94
(
-3.09%
)
Dow Jones
40,345.41
(
-1.01%
)
Brent Oil
70.89
(
-0.71%
)
Bitcoin
54,284.53
(
0.62%
)
Post# of 253055
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

rfj1862

Send PM Follow Ignore
Followers 39
Posts 1714
Boards Moderated 0
Alias Born 10/05/2005

rfj1862

Re: donotknowityet post# 39889

Tuesday, 12/26/2006 12:11:09 PM

Tuesday, December 26, 2006 12:11:09 PM

Post# of 253055
AEZS

Dunno,

I'm completely unconcerned about cetrorelix or SPPI's product. Both are GnRH blockers (with serious limitations), both are injectables.

Cetrorelix, Lucrin, and other GnRH blockers have no chance whatsoever if Proellex makes it to market.

That said, I agree that AEZS appears to be a compelling investment, just not for cetrorelix in endometriosis. I'm going to do more DD.

I pulled my 17.99 GTC on RPRX. I believe the company should be valued at ~$20-$25 right now.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up